Postmenopausal Women With Osteoporosis

6
Pipeline Programs
6
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
6
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 5 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Celltrion
CelltrionKorea - Incheon
1 program
1
CT-P41Phase 31 trial
Active Trials
NCT04757376Completed479Est. Nov 2023
Sandoz
SandozAustria - Kundl
1 program
1
GP2411Phase 31 trial
Active Trials
NCT03974100CompletedEst. Apr 2022
mAbxience
mAbxienceSwitzerland - Lugano
1 program
1
MB09Phase 31 trial
Active Trials
NCT05338086Completed558Est. May 2024
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QLG2128Phase 31 trial
Active Trials
NCT06898060Not Yet RecruitingEst. May 2027
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
RomosozumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT01631214Completed4,093Est. Jun 2017
Alvogen
AlvogenNJ - Morristown
1 program
1
Test groupPhase 31 trial
Active Trials
NCT01581320Completed201Est. Sep 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Qilu PharmaceuticalQLG2128
mAbxienceMB09
CelltrionCT-P41
SandozGP2411
AmgenRomosozumab
AlvogenTest group

Clinical Trials (6)

Total enrollment: 5,331 patients across 6 trials

NCT06898060Qilu PharmaceuticalQLG2128

To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

Start: Jun 2025Est. completion: May 2027
Phase 3Not Yet Recruiting
NCT05338086mAbxienceMB09

A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.

Start: Mar 2022Est. completion: May 2024558 patients
Phase 3Completed
NCT04757376CelltrionCT-P41

A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis

Start: Jun 2021Est. completion: Nov 2023479 patients
Phase 3Completed
NCT03974100SandozGP2411

Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

Start: Jul 2019Est. completion: Apr 2022
Phase 3Completed
NCT01631214AmgenRomosozumab

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

Start: May 2012Est. completion: Jun 20174,093 patients
Phase 3Completed
NCT01581320AlvogenTest group

Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis

Start: Dec 2011Est. completion: Sep 2012201 patients
Phase 3Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space